Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome

Medical Science Monitor

Volumn 11, Issue 6, 2005, Pages

  Mikaszewska Sokolewicz, Małgorzata ^a   Mayzner Zawadzka, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Ovarian hyperstimulation syndrome; Recombinant human activated protein C (rhAPC); Severe sepsis

Indexed keywords

ADRENALIN; ALBUMIN; ANTICOAGULANT AGENT; CARBAPENEM; CIPROFLOXACIN; DOBUTAMINE; DOPAMINE; DROTRECOGIN; ENOXAPARIN; FRESH FROZEN PLASMA; FUROSEMIDE; MEROPENEM; NORADRENALIN; PARACETAMOL; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SEVERITY; ECHOGRAPHY; EMBRYO; FATALITY; FEMALE; FERTILIZATION IN VITRO; FEVER; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; INFERTILITY; INFLAMMATION; MULTIPLE ORGAN FAILURE; OVARY DISEASE; PREGNANCY; SCORING SYSTEM; SEPSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; APACHE; CARDIAC OUTPUT; FEMALE; HEART RATE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; PLATELET COUNT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 21344472973     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. WHO. Making Pregnancy Safer. Februar 2001
2. Webb S: The role of mediators in sepsis resolution Advances In sepsis. 2002; 2: 8-14
3. Ong A, Eisen V, Rennie D et al: The pathogenesis of ovarian hyperstimulation syndrome: a possible role of ovarian renin. Cli. Endocrinol. (OXf), 1991; 34: 43-49
4. McElhinney B, McLure N: Ovarian hyperstimulation syndrome. Baillieres Clinical Obstetrics and Gynecology, 2000; 14: 103-122
5. Loret De Mola JR, Flores JP, Baumgardner GP et al: Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome; immunohistochemical localization of interleukin-6 signal, Obstet Gynecol, 1996; 87:4. 581-86
6. Pellicer A, Albert C, Mercader A et al The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-beta.interleukin-6, and vascular endothelial growth factor. Fertility and Sterility, 1999; 71: 482-89
7. Kinasevitz GT, Yan SB, Basson B et al: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microrganisam. CCM, 2004
8. Levi M, Van der Pol: The central role of endothelium in the crosstalk between coagulation and inflamation in sepsis. Advances in Sepsis, 2004; 3: 91-97
9. Aird WC: The role of endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood, 2003; 101, 3765-77
10. Goldman M, Blajchman MA: Blood Products-Associated Bacterial Sepsis. Transf Med Rev, 1991; 5: 73-83
11. Lee JH: Workshop on Bacteria Contamination of Platelet CBER, FDA September 24, 1999. http: //www.fda.gov/cber/workshop-min.htm June 1, 2000)
12. Issa NC, Rodney L Thompson MD: Staphylococcal toxic shock syndrome. Postgraduate Medicine, 2001, 110(4):
13. Andersen DJ, Murdoch DR, Sexton DJ et al: Risk factors of infective endocarditis in patients with enterococcal bacteriemia: a case control study Infection, 2004; 32: 72-77
14. Bernard GR, Vincent JL, Laterre PF et al: Efficacy and safety of recombinant Human Activated Protein C for severe sepsis. N Eng J Med, 2001; 344: 099-709
15. Mikaszewska-Sokolewicz M, Nierebinska M, Mayzner Zawadzka E: The use of drotrecogin alfa (activated) in severe sepsis-description of two cases Med Sci Monit. 2003; 9(8): CS80-87
16. Laterre PF, Witteboe X: Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis - practical aspects at the bedside and patient identification. Crit Care, 2003; 7(6): 445-50
17. Dellinger RP, Carlet JM, Masur H et al: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med, 2004; 30: 536-55
18. Laterre PF, Heiselman D: Management of patients with severe sepsis, treated by drotrecogin alfa (activated). Am J Surg. 2002; 184: S39-46